Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — September 2025

Genmab — September 2025

Planlagt Fastgjort Låst Flyttet Genmab
283 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #231

    Genmabs topchef om gigantopkøb: Timingen er perfekt https://proinvestor.com/investornyt/1366245/genmabs-topchef-om-gigantopkob-timingen-er-perfekt

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #232

      Genmab hæves til "køb" efter kæmpeopkøb af Sydbank https://proinvestor.com/investornyt/1366244/genmab-haeves-til-kob-efter-kaempeopkob-af-sydbank

      1 Reply Last reply
      0
      • G Offline
        G Offline
        Goose3
        wrote on sidst redigeret af
        #233

        Novo har sendt BLA ind på Mim8. Mener Genmab får en ciffer royalties på produktet.

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #234

          Jan er den C25-CEO med hænderne mest på kogepladen, så han har i høj grad privatøkonomiske interesser på spil.

          1 Reply Last reply
          0
          • R Offline
            R Offline
            Raun
            wrote on sidst redigeret af
            #235

            Mon vi skal ende i plus?

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #236

              Genmab kunne ikke have købt for et par måneder siden. Så havde jorden rystet under dem. Timing er alt 😉

              1 Reply Last reply
              0
              • L Offline
                L Offline
                LP90
                wrote on sidst redigeret af
                #237

                shorts er steget med 0,10% i dag ???

                1 Reply Last reply
                0
                • R Offline
                  R Offline
                  Raun
                  wrote on sidst redigeret af
                  #238

                  @Solsen kl.16.11 - Meget enig 🙂

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #239

                    Udløser mim8 ikke en milepæl? Royalties er mid single digit.

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      ProinvestorNEWS
                      wrote on sidst redigeret af
                      #240

                      Mandagens aktier: Genmab i udsat rolle i positivt C25 https://proinvestor.com/investornyt/1366319/mandagens-aktier-genmab-i-udsat-rolle-i-positivt-c25

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #241

                        before the current CEO, merus had founder Ton Logtenberg as CEO. He is a Professor at Utrecht University, just like Jan. They go back a long time , for example this is an article they co-authored in 1999 https://aacrjournals.org/cancerres/article/59/22/5778/505642/Antitumor-Immune-Effector-Mechanisms-Recruited-by

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #242

                          'H.C. Wainwright downgraded Merus (MRUS) to Neutral from Buy with a price target of $97, down from $135'

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #243

                            Today’s deal was viewed favorably by industry observers, with William Blair analysts pointing to predicted peak sales of $3 billion to $4 billion for petosemtamab in head and neck cancer alone as proof that the acquisition is a “positive” for Genmab. https://www.fiercebiotech.com/biotech/genmab-pays-8b-buy-merus-and-phase-3-stage-bispecific-wowed-analysts

                            1 Reply Last reply
                            0
                            • R Offline
                              R Offline
                              Raun
                              wrote on sidst redigeret af
                              #244

                              Det giver jo god mening 🙂

                              1 Reply Last reply
                              0
                              • R Offline
                                R Offline
                                Raun
                                wrote on sidst redigeret af
                                #245

                                Ovenstående som svar på E L kl. 20.11

                                1 Reply Last reply
                                0
                                • R Offline
                                  R Offline
                                  Raun
                                  wrote on sidst redigeret af
                                  #246

                                  sorry kl. 20.06 🙂

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #247

                                    😉

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #248

                                      Leerink Partners raised its price target on Genmab A/S (NASDAQ:GMAB) to $34.00 from $32.00 on Monday, while maintaining an Outperform rating following the company’s proposed acquisition of Merus https://www.investing.com/news/analyst-ratings/leerink-partners-raises-genmab-stock-price-target-on-merus-acquisition-93CH-4261527

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #249

                                        New trial - Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL) (CLEAR) https://clinicaltrials.gov/study/NCT07197307

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #250

                                          Spændende forsøg med Zylonta fra ADC Therapeutics og Epco. Zylonta viser gode takter med Columvi https://ir.adctherapeutics.com/press-releases/press-release-details/2025/ADC-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Operational-Update/default.aspx Meddelelsen viser også, at ADC kæmper med økonomien.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper